Global Brachytherapy Treatment Planning Systems Market Size (2024 - 2029)

Brachytherapy Treatment Planning Systems Market Analysis

The Brachytherapy Treatment Planning Systems Market is projected to register a CAGR of 9.30% during the forecast period (2022-2027).

During the pandemic, radiation oncology departments across the country implemented strict guidelines, including temperature checks for patients and staff members, prescreening for COVID-19 symptoms before each patient visit, social distancing in the waiting room, limiting visitors, providing surgical masks to patients, and personal protective equipment for staff members, as part of their respective hospitals' initiatives. As per the study published in January 2021, by Advances in Radiation Oncology, titled ''The Impact of COVID-19 on Brachytherapy During the Pandemic: A Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience, six patients elected to undergo external beam radiation therapy (EBRT) followed by a brachytherapy boost for unfavorable intermediate- and high-risk diseases. Since elective surgeries were canceled within our system during the pandemic, 4 patients were treated with EBRT with or without androgen deprivation therapy (ADT) only. Despite the challenges, the health care system faced during the pandemic, most patients with cancer were safely treated with minor treatment delays and interruptions. Thus, due to the COVID-19 imposed restrictions, the was significantly impacted. However, with the increase in cardiac surgeries, the demand for brachytherapy treatment planning systems is expected to boost the growth of the market.

The increasing prevalence of cancerous disorders is expected to drive the market. The increasing cancer burden is one of the major factors driving the market. According to the International Agency for Research on Cancer (IARC), the global incidence of cancer in 2020 was estimated to be around 19.3 million. This is expected to increase to 24.6 million by the year 2030. Furthermore, breast cancer is among the most common cancer, with around 2.26 million new cases in 2020. Moreover, according to the Globocan 2020 estimates, in 2020, there were approximately 19.3 million cancer cases detected across the globe and some of the most common cancers detected were prostate cancer (7.3%), breast cancer (11.7%), colorectal cancer (10.0%), and lung cancer (11.4%). Further estimates predict a sharp increase of 47% in the caseload in 2040 as compared to 2020. According to the Globocan estimates, there would be 28.4 million new cancer cases diagnosed in 2040 across the globe. With the advent of breakthrough technologies capable of dramatically impacting the industry, the radiation therapy sector is constantly evolving and progressing. The industry is expected to have profitable growth in the next years because of improving healthcare infrastructure and rising healthcare spending.

Furthermore, key participants are focusing on growth opportunities in emerging economies with the development of healthcare infrastructure and growing digital healthcare literacy. Furthermore, favorable government initiatives and the promotion of public-private partnerships in cancer care and radiation therapy will boost product innovation and development. For instance, the Australian government launched Victorian Cancer Plan 2020-2024 to improve cancer care strategies and cancer outcomes through early detection and timely treatment. In 2019, Barwon Health Foundation collaborated with Varian Medical Systems to inaugurate Andrew Love Cancer Center Chemotherapy Day Ward and Oncology Pharmacy to improve the accessibility of brachytherapy treatment planning solutions. Additionally, in September 2020, the company announced the launch of a new linear accelerator called Elekta Harmony in the market.

However, shortage of healthcare personnel in information technology and radiology sector and cybersecurity and privacy concerns are expected to hinder the market growth during the forecast period.

Brachytherapy Treatment Planning Systems Industry Segmentation

As per the scope of this report, Brachytherapy is a type of internal radiation therapy in which a radiation source is contained in seeds, ribbons, or capsules that are implanted in or near the tumor. The treatment planning system comprises software which used basically in this procedure. Brachytherapy treatment planning is used to determine the optimal source strength or dwell times and source distribution and loading patterns. It is also used to document the isodose distribution, target, and critical organ doses. The system serves as guidance to future patient management. Such systems used in these procedures are called Brachytherapy Treatment Planning Systems. Brachytherapy is a localized treatment that only affects a small area of your body. It is commonly used to treat head and neck cancers, as well as breast, cervical, prostate, and eye malignancies. The Brachytherapy Treatment Planning Systems Market is segmented by Component (Auto-Contouring Software, Multi-Modality Software, PET/CT Deformable Software, and DICOM-RT Software), By Technique (3D Image Reconstruction, In-Room Imaging, and Image Registration using Graphics Processor Unit) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.